CL2017001982A1 - New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein. - Google Patents

New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein.

Info

Publication number
CL2017001982A1
CL2017001982A1 CL2017001982A CL2017001982A CL2017001982A1 CL 2017001982 A1 CL2017001982 A1 CL 2017001982A1 CL 2017001982 A CL2017001982 A CL 2017001982A CL 2017001982 A CL2017001982 A CL 2017001982A CL 2017001982 A1 CL2017001982 A1 CL 2017001982A1
Authority
CL
Chile
Prior art keywords
diagnosis
tau protein
pyridinemethylsulfinylbenzoxazoles
radiolabelled
compositions
Prior art date
Application number
CL2017001982A
Other languages
Spanish (es)
Inventor
Maccioni Barahona Ricardo
Rojo Castillo Leonel
Quiñones Sepúlveda Luis
Original Assignee
Neuroinnovation Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroinnovation Ltda filed Critical Neuroinnovation Ltda
Priority to CL2017001982A priority Critical patent/CL2017001982A1/en
Publication of CL2017001982A1 publication Critical patent/CL2017001982A1/en
Priority to PCT/CL2018/050059 priority patent/WO2019023815A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente invencion corresponde a compuestos piridinmetilsulfinilbenzoxazoles y piridinmetilsulfinilbenzotiazoles, marcados radiactivamente o con fluorescencia y sus composiciones, como biornarcadores especificos para el diagnóstico de enfermedades neurodegenerativas y patológicas involucradas con Ia proteína tau tales como AIzheimer y otras demencias. Conforme a Ia presente invención las técnicas donde se pueden emplear las moléculas descritas pueden ser: Tomografia Axial Computarizada (CAT), resonancia magnetica nuclear (NMR), tanto estructural (sNMR) como funcional NMR (fNMR), tomografia computarizada de emisión de fotón único (SPECT) y Ia tomografia de emisión de positrones (PET). De esta forma Ia invención proporciona una herrarnienta farmacolóqicamente segura, con una elevada afinidad y selectividad por estructuras proteicas de proteína tau, lo cual permite establecer una aplicación, método o uso de dichos agentes pare la identificación y diagnóstico de enfermedades neurodegenerativas, tau patologias, de preferencia enfermedad de Alzheirner.</p><p> The present invention corresponds to pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinylbenzothiazoles compounds, radiolabelled or fluorescently labeled and their compositions, as specific biornarcadores for the diagnosis of neurodegenerative and pathological diseases involved with tau protein such as AIzheimer and other dementias. According to the present invention, the techniques where the described molecules can be used can be: Computed Axial Tomography (CAT), nuclear magnetic resonance (NMR), both structural (sNMR) and functional NMR (fNMR), single photon emission computed tomography (SPECT) and positron emission tomography (PET). In this way, the invention provides a pharmacologically safe tool, with a high affinity and selectivity for protein structures of tau protein, which allows establishing an application, method or use of said agents for the identification and diagnosis of neurodegenerative diseases, tau pathologies, of Alzheirner disease preference. </p>

CL2017001982A 2017-08-03 2017-08-03 New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein. CL2017001982A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2017001982A CL2017001982A1 (en) 2017-08-03 2017-08-03 New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein.
PCT/CL2018/050059 WO2019023815A1 (en) 2017-08-03 2018-07-30 New compounds derived from pyridine methyl sulfinyl benzoxazoles and pyridine methyl sulfinyl benzothiazoles, tagged radioactively or fluorescently, and compositions thereof as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involving tau protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017001982A CL2017001982A1 (en) 2017-08-03 2017-08-03 New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein.

Publications (1)

Publication Number Publication Date
CL2017001982A1 true CL2017001982A1 (en) 2018-04-20

Family

ID=63046510

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001982A CL2017001982A1 (en) 2017-08-03 2017-08-03 New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein.

Country Status (2)

Country Link
CL (1) CL2017001982A1 (en)
WO (1) WO2019023815A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850308B (en) * 2022-11-07 2024-06-11 淮阴工学院 BODIPY near infrared fluorescent probe containing electron donor and acceptor groups for recognizing Abeta fibers and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193984A (en) * 1984-03-14 1985-10-02 Tokyo Tanabe Co Ltd Benzoxazole derivative
CA1341314C (en) * 1984-07-06 2001-11-06 David Cox Derivatives of benzimidazole, benzothiazole and benzoxazole
JPS62207271A (en) * 1986-03-06 1987-09-11 Yamanouchi Pharmaceut Co Ltd Condensed ring compound substituted with 2-pyridylmethylthio group or 2-pyridylmethylsulfinyl group

Also Published As

Publication number Publication date
WO2019023815A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
CL2018001414A1 (en) Antibodies against cd73 and their uses (divisional application 201701296)
MX2024001192A (en) Anti-lag-3 antibodies and methods of use thereof.
CL2020002314A1 (en) Anti-cd73 antibodies and methods of using them
UY36738A (en) TGR5 MODULATORS AND SAME USE METHODS
CL2017002244A1 (en) Specific bispecific antibodies for fap and dr5, specific antibodies for dr5 and methods of use. (divisional application 2829-2015).
CL2017002237A1 (en) Binding protein of il-18 (il-18bp) and antibodies in inflammatory diseases.
CO2017005374A2 (en) Inhibitors of interleukin 1 receptor associated kinase 4 (irak4) derived from n- [6- (hydroxymethyl) -2h-indazol-5-yl] pyridine-2-carboxamide, compositions comprising them and methods of preparation
PE20171764A1 (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES, AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY BIND CD3 AND / OR CD123
BR112015025140A2 (en) 2-phenylimidazo [1,2-a] pyrimidines as imaging agents
Gasser et al. Understanding Haemonchus contortus better through genomics and transcriptomics
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
JP2014221779A5 (en)
MX2016016384A (en) PIRROLO [2,3-C] PIRIDINAS AS AGENTS OF FORMATION OF PICTURES FOR NEUROFIBRILLARY BALLS.
MX2021014952A (en) SPECIFIC BINDING MOLECULE FOR CD73 AND USE OF THE BINDING MOLECULE.
BR112017003472A2 (en) antibodies, antibody fab fragment and method for treating an inflammatory disease
CL2017002082A1 (en) New specific proteins for pioverdine and pyoquelin
CL2017001592A1 (en) Radiopharmaceutical complexes.
MX2018016279A (en) COMPOUNDS FOR IMAGE FORMATION OF AGGREGATES OF TAU PROTEINS.
MX348733B (en) PEPTIDE RADIO TRAINER COMPOSITIONS.
Moyanova et al. Present status and future challenges of electroencephalography-and magnetic resonance imaging-based monitoring in preclinical models of focal cerebral ischemia
CO2020008834A2 (en) New method to prepare compound for imaging
BR112022009471A2 (en) HIGHLY EFFICIENT MYELOPEROXIDASE-ACTIVABLE IMAGING AGENTS
CO2020005371A2 (en) Anti-apoc3 antibodies and methods of using them
CL2017001982A1 (en) New compounds derived from pyridinemethylsulfinylbenzoxazoles and pyridinemethylsulfinibenzothiazoles, radiolabelled or fluorescently labeled and their compositions, as specific biomarkers for the diagnosis of neurodegenerative diseases and pathologies involved with the tau protein.
ES2470816B1 (en) Recombinant protein and uses in the diagnosis of multiple sclerosis